Encouraging Fragile X Data for Seaside Therapeutics
Seaside Therapeutics reported encouraging results from the largest randomized study conducted to date in patients with Fragile X syndrome.
randall l. carpenter
Seaside Therapeutics Secures $30M to Fight Autism
Seaside Therapeutics has secured $30 million in funding from a private, unnamed family investment firm committed to finding treatments for autism and Fragile X syndrome.